Biofrontera Nears Potential Breakthrough with FDA Decision
AI Prediction of Biofrontera Inc. Common Stock (BFRI)
Biofrontera is poised for significant milestones in 2026, with potential FDA approval and expanded commercial endeavors likely to drive stock performance.
Biofrontera Inc., a small-cap biopharmaceutical company, specializes in dermatological conditions treated with photodynamic therapy (PDT). The company already markets Ameluz, a topical gel for actinic keratosis, and the RhodoLED lamp. Key catalysts include an upcoming PDUFA date in September 2026 for sBCC and potential label expansions. These developments could significantly increase the market size and enhance commercial credibility, especially given the recent positive Phase 3 results and ongoing commercialization efforts in the U.S. market. Investors should monitor these regulatory milestones closely as they are likely to impact the stock's price significantly.
BFRI Report Information
Prediction Date2026-03-27
Close @ Prediction$0.81
Mkt Cap7m
IPO Date2021-10-29
AI-derived Information
Recent News for BFRI
- Mar 20, 9:01 pm — Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
- Mar 19, 12:44 pm — Biofrontera Inc. Q4 2025 Earnings Call Summary (Moby)
- Mar 9, 12:00 pm — Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why (Zacks)
- Feb 5, 9:55 am — Biofrontera Inc. (BFRI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
- Feb 5, 9:40 am — Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year? (Zacks)
- Nov 13, 4:06 pm — Biofrontera Inc (BFRI) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
- Nov 10, 8:25 am — Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
- Nov 7, 5:40 pm — Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates (Zacks)
- Nov 5, 5:25 pm — PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates (Zacks)
- Nov 5, 8:20 am — Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
- Oct 24, 8:55 am — Biofrontera Inc. close purchase of all Ameluz, RhodoLED U.S. assets (TipRanks)
- Aug 25, 10:30 am — BC-Most Active Stocks (Associated Press Finance)
NDAPR (News-Driven AI Prediction Revision) events for BFRI
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest